>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

0.57 -0.03 (-5.48%) 10/02/2026
Jasper Therapeutics, Inc. (JSPR)
Performance
Historical returns
1D
-5.48%
1W
-9.71%
1M
-19.82%
3M
31.96%
6M
-17.85%
1Y
-76.64%
5Y
-99.39%
Snapshot
Key statistics
Close
0.57
Change
-0.03
Change %
-5.48%
Open
0.60
Day Range
0.56 – 0.62
Volume
235,084
Avg Vol (20d)
349,556
Rel Vol
0.67x
52W Range
0.32 - 2.69
vs 52W High
-78.99%
vs 52W Low
78.24%
Gap
-0.04
Market Cap
USD 9.19M
Beta
3.05
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Create a free account
Bull vs Bear
3 bullish · 3 bearish points
Bullish view
  • Has recovered 65.7% off the 52-week low of $0.34.
  • Outperformed the S&P 500 by 18.8% over the last quarter (+21.3% against +2.4%).
  • The Aug 2026 quarter beat on EPS by $0.17 (62.7% above consensus).
Bearish view
  • Trades 42.1% below its 200-day average, a downtrend still intact.
  • Still 78.3% below its 52-week high of $2.60.
  • Missed consensus EPS in 4 of the last 8 quarters.
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Oct 2
2026
$0.57 5.48%Latest
Jasper Therapeutics fell 5.48% to $0.57, though on light volume (0.7× the 20-day average). This was largely stock-specific: the S&P 500 gained 0.74% while Healthcare peers (XLV) fell 0.01% that session, leaving about 5.5 points of the move unexplained by its sector. Shares closed near the session low (5% of the day's range). The move left the stock 78.3% below its 52-week high.
Sep 30
2026
$0.58 7.26%
Jasper Therapeutics fell 7.26% to $0.58, on 1.4× average volume. This was largely stock-specific: the S&P 500 fell 0.21% while Healthcare peers (XLV) fell 1.35% that session, leaving about 5.9 points of the move unexplained by its sector. Shares opened with a 0.86% gap down and closed near the session low (10% of the day's range).
Sep 23
2026
$0.57 9.01%
Jasper Therapeutics fell 9.01% to $0.57. This was largely stock-specific: the S&P 500 fell 0.72% while Healthcare peers (XLV) fell 0.64% that session, leaving about 6.8 points of the move unexplained by the market after adjusting for a 3.05 beta. Shares opened with a 0.75% gap up and reversed through the session and closed near the session low (0% of the day's range).
Sep 17
2026
$0.63 9.16%
Jasper Therapeutics rose 9.16% to $0.63, its biggest one-day gain in 1 month, though on light volume (0.7× the 20-day average). Roughly 4.9 points were stock-specific — the S&P 500 gained 1.39% while Healthcare peers (XLV) rose 0.62% alongside it. Shares opened with a 1.57% gap up.
Sep 15
2026
$0.57 9.91%
Jasper Therapeutics fell 9.91% to $0.57, its biggest one-day drop in 4 weeks. This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.05% that session, leaving about 8.5 points of the move unexplained by the market after adjusting for a 3.05 beta. Shares opened with a 1.14% gap up and reversed through the session, closed near the session low (0% of the day's range) and marked a 5th consecutive decline.
Sep 11
2026
$0.66 5.77%
Jasper Therapeutics fell 5.77% to $0.66, its biggest one-day drop in 3 weeks, though on light volume (0.5× the 20-day average). This was largely stock-specific: the S&P 500 gained 0.85% while Healthcare peers (XLV) fell 0.18% that session, leaving about 5.6 points of the move unexplained by its sector. Shares opened with a 1.06% gap down, closed near the session low (1% of the day's range), lost their 50-day moving average and marked a 3rd consecutive decline.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month0.54 +3.84%
on 09/24/26
Open 0.70
0.74 -23.62%
on 09/08/26
-0.14 (-19.82%)
since 09/02/26
3-Month0.42 +33.59%
on 07/06/26
Open 0.47
1.03 -45.13%
on 07/17/26
+0.10 (+21.29%)
since 07/06/26
6-Month0.32 +78.24%
on 06/29/26
Open 0.69
1.12 -49.54%
on 04/20/26
-0.12 (-17.85%)
since 04/02/26
YTD0.32 +78.24%
on 06/29/26
Open 1.84
2.07 -72.70%
on 01/07/26
-1.27 (-69.28%)
since 01/02/26
52-Week0.32 +78.24%
on 06/29/26
Open 2.40
2.69 -78.99%
on 10/20/25
-1.83 (-76.45%)
since 10/01/25
5-Year0.32 +78.24%
on 06/29/26
Open 151.20
188.80 -99.70%
on 10/15/21
-150.63 (-99.63%)
since 09/24/21
New Highs
Historical highs
5-Day
0×
-9.71% from peak
1-Month
2×
-20.33% from peak
3-Month
7×
-36.71% from peak
6-Month
6×
-46.68% from peak
YTD
2×
-72.43% from peak
52-Week
3×
-78.26% from peak
2-Year
9×
-97.71% from peak
3-Year
29×
-98.12% from peak
5-Year
2×
-99.66% from peak
10-Year
n/a
not enough history
Financial SnapshotFY 2025
Full financials
Revenue
n/a
Net Income
-USD 75.80M
+6.4% YoY
EPS
-3.95
-19.2% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 74.75M
Free Cash Flow
-USD 77.17M
ROE
-1,826.1%
ROA
-211.9%
Debt / Equity
0.30x
net debt -USD 27.46M
Cash & Equiv.
USD 28.69M
News
All news
09/15 16:05 ET · globenewswire.com
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D.
09/09 08:00 ET · globenewswire.com
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate...
08/14 11:00 ET · globenewswire.com
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders
07/17 13:08 ET · benzinga.com
Jasper Closes Kira Deal, Extends Cash Runway
Jasper Therapeutics Inc. (NASDAQ:JSPR) on Thursday said it completed its all-stock acquisition of Kira Pharmaceuticals, bringing the two biotechnology companies together to advance a unified pipeline of therapies targeting immune-mediated and autoantibody-driven diseases.
07/16 17:15 ET · globenewswire.com
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders
06/03 10:56 ET · zacks.com
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for...
06/01 08:00 ET · globenewswire.com
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous...
05/14 16:05 ET · globenewswire.com
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous...

Market News ×
Loading news…